Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moderna, Inc.MRNA · Entity 2025 | Chief Financial Officer | October 05, 2026 | October 07, 2026 |
| REVVITY, INC.PKI · Entity 3382 | Please See Remarks | June 24, 2022 | June 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moderna, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,125 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 1,454 · Balance 60,829 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2026-10-05 · Tax withholding · Disposed 704 · Balance 60,125 F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Exercise / conversion · Disposed 1,454 · Balance 0 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
REVVITY, INC.
Report date June 24, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,577 |
Ending reported balance
After 2022-06-24 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-06-24 · Sale · Disposed 2,072 · Balance 30,530 F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Mock on May 23, 2022. F2: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $144.27 to $145.11. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Row 2 · 2022-06-24 · Sale · Disposed 2,290 · Balance 28,240 F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Mock on May 23, 2022. F3: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $145.27 to $146.26. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Row 3 · 2022-06-24 · Sale · Disposed 663 · Balance 27,577 F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Mock on May 23, 2022. F4: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $146.28 to $146.40. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Mock on May 23, 2022.
F2: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $144.27 to $145.11. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
F3: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $145.27 to $146.26. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
F4: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $146.28 to $146.40. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000185 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 704 | $190.01 | $133,767.04 |
DisclosureSEC source: 0001682852-26-000185 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,125 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000185 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,836 | $0.00 Strike: $30.96 | $0.00 |
DisclosureSEC source: 0001682852-26-000174 · form4.xml · derivative · entry 4 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,642 Underlying: Common Stock · 19,836 shares Expires 2035-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. F2 · derivative.exercise_date: 25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:25 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $134.49 | $2,017,350.00 |
DisclosureSEC source: 0001682852-26-000174 · form4.xml · nonDerivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,375 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:25 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 19,836 | $134.49 | $2,667,743.64 |
DisclosureSEC source: 0001682852-26-000174 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,375 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 19,836 | $30.96 | $614,122.56 |
DisclosureSEC source: 0001682852-26-000174 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. Read SEC document |
| September 04, 2026 Filed Sep 8, 2026 21:02 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 11,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000172 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,179 Underlying: Common Stock · 11,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 04, 2026 Filed Sep 8, 2026 21:02 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 5,704 | $148.87 | $849,154.48 |
DisclosureSEC source: 0001682852-26-000172 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,375 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| September 04, 2026 Filed Sep 8, 2026 21:02 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 11,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000172 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:52 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000165 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,755 Underlying: Common Stock · 2,475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:52 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 1,197 | $140.34 | $167,986.98 |
DisclosureSEC source: 0001682852-26-000165 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,282 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:52 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000165 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000155 · form4.xml · derivative · entry 6 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 658 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 160 | $142.77 | $22,843.20 |
DisclosureSEC source: 0001682852-26-000155 · form4.xml · nonDerivative · entry 4 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,004 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000155 · form4.xml · nonDerivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 774 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000155 · form4.xml · derivative · entry 5 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,642 Underlying: Common Stock · 774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 375 | $149.66 | $56,122.50 |
DisclosureSEC source: 0001682852-26-000155 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,835 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000155 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 20:30 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000129 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,454 Underlying: Common Stock · 1,452 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 20:30 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 703 | $72.50 | $50,967.50 |
DisclosureSEC source: 0001682852-26-000129 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,436 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 20:30 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,452 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000129 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:30 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 11,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000117 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,976 Underlying: Common Stock · 11,798 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:30 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 5,705 | $51.59 | $294,320.95 |
DisclosureSEC source: 0001682852-26-000117 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,687 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:30 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 11,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000117 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000115 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,230 Underlying: Common Stock · 2,475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 1,197 | $47.19 | $56,486.43 |
DisclosureSEC source: 0001682852-26-000115 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,594 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000115 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 28, 2026 Filed May 29, 2026 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000109 · form4.xml · derivative · entry 6 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 987 Underlying: Common Stock · 328 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 28, 2026 Filed May 29, 2026 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 159 | $47.61 | $7,569.99 |
DisclosureSEC source: 0001682852-26-000109 · form4.xml · nonDerivative · entry 4 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,316 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| May 28, 2026 Filed May 29, 2026 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 328 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000109 · form4.xml · nonDerivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 773 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000109 · form4.xml · derivative · entry 5 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,416 Underlying: Common Stock · 773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 374 | $47.03 | $17,589.22 |
DisclosureSEC source: 0001682852-26-000109 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,147 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000109 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000053 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,906 Underlying: Common Stock · 1,453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 703 | $50.03 | $35,171.09 |
DisclosureSEC source: 0001682852-26-000053 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,748 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000053 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 11,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000049 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,774 Underlying: Common Stock · 11,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 5,704 | $57.80 | $329,691.20 |
DisclosureSEC source: 0001682852-26-000049 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,998 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 11,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000049 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 49,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000038 · form4.xml · derivative · entry 11 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,569 Underlying: Common Stock · 49,569 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F7 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F7 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 37,639 | $0.00 Strike: $53.57 | $0.00 |
DisclosureSEC source: 0001682852-26-000038 · form4.xml · derivative · entry 10 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,639 Underlying: Common Stock · 37,639 shares Expires 2036-03-01 F6 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 9,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000038 · form4.xml · derivative · entry 9 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,705 Underlying: Common Stock · 9,901 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 774 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000038 · form4.xml · derivative · entry 8 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,189 Underlying: Common Stock · 774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000038 · form4.xml · derivative · entry 7 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,315 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 4,788 | $51.71 | $247,587.48 |
DisclosureSEC source: 0001682852-26-000038 · form4.xml · nonDerivative · entry 6 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,905 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 9,901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000038 · form4.xml · nonDerivative · entry 5 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 375 | $51.71 | $19,391.25 |
DisclosureSEC source: 0001682852-26-000038 · form4.xml · nonDerivative · entry 4 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,792 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000038 · form4.xml · nonDerivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 160 | $51.71 | $8,273.60 |
DisclosureSEC source: 0001682852-26-000038 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,393 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.